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Abstract: The aim of this study was to investigate the effects of a chemical carcinogen, Diethylnitrosamine (DENA), on these
markers, sialic acid (SA), lipid-bound sialic acid (LBSA) and the liver enzymes aspartate aminotransferase, alanine aminotransferase,
and gamma-glutamyltransferase.
In this research 180 male Wistar albino rats were used. Rats were divided equally into three groups. Intraperitoneal (i.p.) injection
of saline was given to rats in the control group. Treatment group I was given i.p. 100 mg/kg-body weight DENA dissolved in saline.
Treatment group II was given i.p. 200 mg/kg-body-weight DENA dissolved in saline. These doses were given to each group just once.
Blood samples were taken from fifteen rats, which were chosen randomly from each group per month during the four months.
Levels of SA and LBSA and activities of ALT, AST and GGT were determined in serum. Significant elevations in the serum levels of
SA and LBSA and activities of ALT, AST and GGT were observed in treatment groups when compared with the controls.
In this study, the high levels of enzyme activities, sialic acid, and lipid-bound sialic acid led to hepatocellular degeneration. The results
suggest that combined evaluation of these markers (SA and LBSA) and liver enzyme activities can be useful in predicting malignant
change.
Key Words: Diethylnitrosamine, sialic acid, lipid-bound sialic acid, liver enzymes, rats.

Dietilnitrosamin’in S›çanlarda Serum Siyalik Asit, Lipid-Ba¤l› Siyalik Asit ve
Transferaz Enzim Aktivitelerine Etkisi
Özet: Bu çal›flman›n amac› kimyasal bir karsinojen olan Dietilnitrosamin (DENA) ‘in serum siyalik asit (SA) ve lipid-ba¤l› siyalik asit
(LBSA) ile alanin transaminaz (ALT), aspartat transaminaz (AST) ve gama-glutamiltransferaz (GGT) enzim düzeylerine etkisini
araflt›rmakt›r.
Çal›flmada 180 difli s›çan kullan›lm›flt›r. S›çanlar kontrol ve deneme gruplar› olarak üçe ayr›lm›flt›r. Her grup 60’ar hayvandan
oluflmufltur. Kontrol grubu olarak kullan›lan ratlara periton içi (i.p) serum fizyolojik verilmifltir. Deneme-I grubuna serum fizyolojik
içinde çözülmüfl 100 mg/kg-vücut a¤›rl›¤›na DENA, Deneme-II grubundaki s›çanlara ise 200 mg/kg-vücut a¤›rl›¤›na DENA i.p. olarak
verilmifltir. Tüm gruplara DENA tek doz olarak verilmifltir. Kan örnekleri dört ay boyunca her ay her bir gruptan rastgele seçilen
s›çanlardan sa¤lanm›flt›r. Serumda SA, LBSA düzeyleri ve ALT, AST, GGT enzim aktiviteleri ölçülmüfltür. Deneme-I ve Deneme-II
gruplar›n›n çal›flma süresince serum SA, LBSA, ALT, AST, GGT ortalama de¤erleri kontrol grubunun de¤erleriyle karfl›laflt›r›ld›¤›nda,
farkl›l›klar istatistiki olarak anlaml› bulunmufltur.
Çal›flma sonuçlar› de¤erlendirildi¤inde, enzim aktiviteleri ile SA, ve LBSA düzeylerindeki art›fllar, karaci¤er hücre dejenerasyonundan
kaynaklanabilece¤ini düflündürmektedir. Sonuçlar, tümör mark›rlar›n›n (SA, LBSA) ve karaci¤er enzim aktivitelerinin beraber
de¤erlendirilmesinin tümöral de¤iflimlerin teflhisinde faydal› olabilece¤ini önermektedir.
Anahtar Sözcükler: Dietilnitrosamin, siyalik asit, lipide ba¤l› siyalik asit, karaci¤er enzimleri, rat.
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Introduction
Diethylnitrosamine (DENA), which has carcinogenic
and toxic effects, can be found in air, water, soil,
workplaces, tobacco smoke, processed meats and
different food (1-3). It may also be derived from the
metabolism of some therapeutic drugs (4).
Administration of DENA to animals has been shown to
cause cancer in liver and, at lower incidences, in other
organs as well (5,6). In liver cancer research with
experimental animals, DENA is used either as a complete
carcinogen or as an initiator in multistage models (7).
When used as a tumour initiator, DENA is usually given at
a single dose of 200 mg/kg to induce pronounced liver
necrosis and presumably certain gene mutations in some
hepatocytes (8,9). Dunsford et al. (6) used DENA
opportunistically to improve cancer development in liver
cells with enhanced multiplication caused by hepatocyte
necrosis.
The administration of carcinogenic substances may
bring about changes in enzyme levels arising from clonic
proliferation, so it is of some importance to analyse
enzyme activity variation quantitatively in order to
understand the processes involved (9,10). DENA has
effects on the serum and tissue-specific enzymes. Some
research has indicated that it increases the activity of ALT,
AST, GGT, B-glycuronidase glycose-6 phosphate
dehydrogenase (G-6-PDH), and hexokinase and decreases
the activity of lactate dehydrogenase (LDH), glycose-6
phosphatase (G.6.P.az), malate dehydrogenase (MDH),
adenosin triphosphatase (ATPaz), cytochrome reductase
and uridine diphospho-glucuronyl transferase (11-14).
In the research of Guiliani and Zaki (15), i.p. DENA
were given to rats for 5 days in dose of 2 mg/kg body
weight. It was determined that serum ALT and AST
enzyme activity increased. Özkurt (16) determined that
the activities of LDH increased and the activities of citrate
synthetase decreased in the first and third months after
DENA was given to rats. Bak›r et al. (12) observed that
the activities of glucose-6-phosphate-dehydrogenase and
hexokinase increased, the activities of malate
dehydrogenase decreased in the livers of rats given DENA
as a single dose of 100 mg/kg body weight. Moor et al.
(11) followed the results of their experiment, in which a
single dose of i.p. DENA (0.1, 0.2, 0.4 mmol/kg-body
weight) was given to mice, during 32 weeks. According
to their results, liver damage was observed in the 8th
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week but hepatic nodules were determined in the 8th
month.
Biological markers can be used to monitor cancer,
predict the therapeutic response and prognosis of cancer,
and in some certain situations even diagnose cancer.
These markers, referred to as tumour markers, naturally
occur or are modified molecules that can be measured in
serum, plasma, or other body fluids and their
concentration changes in the presence of cancer
(2,17,18).
N-acetylneuraminic acid (sialic acid) is an N-acyl
derivative of neuraminic or acid amino sugar derivative,
derived from N-acetylmannosamine and pyruvic acid. It is
an important constituent of glycoproteins and glycolipids.
N-acetylneuraminic acid occurs in many polysaccharides,
glycoproteins, and glycolipids in animals and bacteria
(17,19). The correlation between levels of sialic acid and
sialic acid-containing glycolipids (gangliosides) in tumours
and serum with the growth characteristics of the tumours
was investigated in transplantable hepatomas and
squamous cell carcinomas initiated with carcinogenic
agents in vivo and in tissue culture (19). Research on the
changes of the glycoprotein and sialoglycoprotein
metabolisms on the surface of tumour cells led to the use
of SA enzymes of glycosil transferase as tumour markers.
Serum SA and LBSA are considered important criteria in
the development of a tumour and its treatment,
particularly to follow up metastasis formation (20-22).
Neoplasms often have an increased concentration of SA
on the tumour cell surface. Sialoglycoproteins and/or
gangliosides are shed or secreted by some of these
tumour cells increasing the concentration of SA and lipidbound sialic acid (LBSA) in the blood (21).
Increased serum levels of SA have been reported in
patients suffering from cancer (22), and alcoholism (23),
and in patients with bacterial infections (20,24),
rheumatoid arthritis (24,25), and various other diseases
(20).
The acute toxicity of DENA to the liver has been well
documented in the literature but whether DENA also
affects the sialic acids, and lipid-bound sialic acid has been
not addressed in these studies.
The aim of this research is to study the toxic effect of
DENA. For this purpose, the level of SA and LBSA, which
are widely considered tumour markers, and the activities
of the enzymes namely ALT, AST and GGT, are examined.
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Materials and Methods
In this research, 180 male Wistar albino rats, which
were 28 days old, were used throughout the study. The
animals were kept under standardized conditions (light
from 06 00 hr to 18 00 hr, 21 ± 2 °C humidity 55%)
with standard rat pellets and water supplied ad libitum.
Rats were randomly divided into three groups
comprised of three to 60 rats per group. At 5 weeks of
age, rats received an intraperitoneal (i.p.) injection of
DENA (Sigma Chemical Co.) or saline. The first one was
the control group and the other two groups were the
treatment groups. Control group: i.p. saline was given to
this group while the treatment groups were given DENA.
Treatment group I: A single dose of DENA (100
mg/kg body weight) dissolved in saline was given i.p. to
rats. Treatment group II: A single dose of DENA (200
mg/kg body weight) dissolved in saline was given i.p. to
rats. After the beginning of the injection of DENA blood
samples were taken from 15 rats in every group for
biochemical parameters once a month during the four
months. Levels of SA and LBSA and activities of ALT, AST

and GGT were determined in the sera. SA and LBSA
analyses were used the Warren thiobarbiturate method
(26). ALT, AST and GGT enzyme reagents were supplied
by Sigma Diagnostics (Sigma Chemical Co. Ltd., Poole,
Dorset, UK) and spectrophotometric assays were
performed. From the beginning of the research, 5 rats
were taken from each group in every 4 weeks, they were
euthanised with sulphuric acid and a systemic autopsy
was carried out.
Statistical analysis: All data from each treatment
groups and control group were analysed using Student’s
t-test.

Results
The levels of serum SA indicate significant statistical
differences in the first and second treatment groups
compared to the control group (P < 0.001). There is also
a significant statistical difference (P < 0.001) with
respect to the levels of serum LBSA between the control
group and treatment groups I and II (Table). When the
activities of serum AST in the first treatment group are

Table. Changes in enzyme activities and Sa and LBSA levels in DENA administrated rats.
Para
Meters

Groups
N = 15

I. Month
X ± SE

II. Month
X ± SE

III. Month
X ± SE

IV. Month
X ± SE

SA
(mg/dl)

Control
Treatment-I
Treatment-II

23.45 ± 0.13
29.90 ± 0.40***
33.65 ± 0.65***

26.89 ± 0.39
35.0 ± 0.49***
41.0 ± 0.41***

30.80 ± 0.38
40.2 ± 0.93***
59.5 ± 1.14***

43.10 ± 0.34
46,00 ± 0.33*
73.3 ± 1.75***

LBSA (mg/dl)

Control
Treatment-I
Treatment-II

17.48 ± 0.29
22.0 ± 1.00***
23.4 ± 1.12***

18.40 ± 0.35
38.19 ± 0.40***
39.6 ± 0.40***

20.70 ± 0.64
41.4 ± 0.46***
43.3 ± 0.60***

21.10 ± 0.55
49,5 ± 1.00***
54.36 ± 0.73***

AST (IU/l)

Control
Treatment-I
Treatment-II

16.71 ± 1.22
19.91 ± 2.62
21.01 ± 1.58*

17.73 ± 0.59
23.03 ± 1.43
29.6 ± 2.42***

21.60 ± 1.02
34.7 ± 1.30***
38.3 ± 1.11***

27.88 ± 0.85
48.8 ± 2.09***
58.2 ± 2.39***

ALT (IU/l)

Control
Treatment-I
Treatment-II

51.48 ± 1.73
61.84 ± 2.53**
77.8 ± 2.98***

58.05 ± 1.94
72.98 ± 3.10**
81.1 ± 1.94***

60.04 ± 1.31
84.0 ± 2.93***
89.7 ± 1.92***

63.34 ± 1.93
94.3 ± 1.76***
97.6 ± 1.33***

GGT (IU/l)

Control
Treatment-I
Treatment-II

1.6 ± 0.16
1.9 ± 0.23
2.1 ± 0.25

1.7 ± 0.15
2.2 ± 0.20
2.8 ± 0.25**

1.8 ± 0.20
2.6 ± 0.22**
3.7 ± 0.38***

2.0 ± 0.21
3.5 ± 0.43**
4.5 ± 0.58***

* , **, *** Significantly ( P < 0.05 , P < 0.01 , P < 0.001) different from control group.
X= mean SE= Standard Error
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compared with the activities in the control group, it is
determined that the activities of enzyme increased. While
this increase was insignificant in the statistical sense in the
first and second month, it was significant in the third and
fourth (P < 0.001) months. It is also determined that the
activities of serum AST in treatment group II increased
compared to the control group. These increases were P <
0.05 in the first month, P < 0.001 in the second, third
and fourth months. The activities of serum ALT in
treatment group I increased compared to the control
group. In the statistical sense, this increase was
significant in the first (P < 0.01), second, third and
fourth months (P < 0.001). It is determined that there
was a significant difference in activities of serum ALT
between treatment group II and the control group. The
difference continued (P < 0.001) throughout the 4
months. The activities of GGT in treatment group I were
increased compared to the activities in the control group.
This increase was statistically insignificant in first and
second months but it was significant in third (P < 0.01)
and fourth (P < 0.001) months. It is also determined that
were increases in the levels of serum GGT in treatment
group II compared to the control group. This increase
was statistically insignificant in the first month but was
significant in the second (P < 0.01) third and fourth (P <
0.001) months.

Discussion
In this research after i.p. DENA injection, the activities
of ALT, AST and GGT, and levels of SA and LBSA
increased in the two treatment groups compared with the
control group. These statistically significant increases
continued during the experimental period.
It is determined that the enzyme activities of serum
ALT, AST and GGT increased in the treatment groups
compared to the control group in the course of 4 months.
These increases are statistically significant and the
increase in the enzyme activities in treatment group II, in
which a high dose of DENA was used, is higher than in
treatment group I (Table).
Hepatospecific enzymes were increased when
hepatocellular damage and these enzymes are activated in
hepatoma (14). AST, ALT, GGT and ALP exhibit high
levels in the abnormally functioning liver, thus
establishing them as an index of liver function recovery
degree (27,28). DENA is not only carcinogenic, as a
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potent alkylating agent, but also inhibits protein
synthesis. After this inhibition, changes in the activity of
enzyme may occur (1,15). It is observed that DENA
causes an increase in some enzyme activities and
decreases in some other enzyme activities (1113,15,16).
AST and ALT activities in blood serum are generally
accepted as an index of liver damage and this tendency is
also known to be distinct in rodents (14). ALT is
recognised to be a highly liver specific enzyme. Also the
measurement of serum GGT is a frequently used
parameter of liver diseases (29). In this study the
activities of serum ALT in treatment group I increased
compared to the control group. This increases was found
significant in the first (P < 0.01), second, third and
fourth months (P < 0.001). It is determined that there
was a significant difference in activities of serum ALT
between treatment group II and the control group. The
difference continued (P < 0.001) throughout the 4
months. AST is not only a specific index to the liver but
also it was distributed in the liver, heart, kidney, skeletal
muscles and brain. However, when the activities of serum
AST in the treatment groups are compared with the
control group, it is determined that the activities of
enzyme increased during the four months. GGT activities
in the serum were also increased, and the highest activity
was observed in the fourth month. These findings are in
agreement with those of Woo-song et al. (14) and
Guiliani and Zaki (15).
This study was designed to evaluate the clinical
application of serum total sialic acid (TSA) in the diagnosis
of liver damage. We thus investigated the effects of DENA
on serum SA and LBSA levels in this study. In many cancer
studies, it is also found that increases in the levels of SA
and LBSA point out the beginning of tumoral formation
as well as metastases formation (22,24,30). The
increases in the levels of LBSA may indicate that
neoplastic deformation occurred in the cells. When the
amount of precursors of ganglioside and of neutral
glycolipid increase, the amount of complex glycolipid
decrease and this event indicates deformation in the cells
(21,30). According to many studies, increases in the
levels of SA and LBSA can be defined as an indicator of a
change in the structure of glycolipid in cell membrane
(20,30).
The levels of serum SA and LBSA were higher in
treatment group II in comparison to the levels in
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treatment group I. These results may emanate from the
difference in doses given to the first and second
treatment groups.
Before macroscopic findings, following up the levels
of SA and LBSA, and the levels of enzymes ALT, AST and

GGT can give an idea about the liver damage caused by
the toxic effect of DENA, which is hepatotoxic and
hepatocarcinogenic. However, this kind of research can
be supported by histopathological examinations in order
to provide in-depth analysis of liver damage.
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